LTRN vs. BTAI, LPTX, GRTS, PRPH, TNXP, ATAI, ENTA, XBIT, IMMP, and ME
Should you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include BioXcel Therapeutics (BTAI), Leap Therapeutics (LPTX), Gritstone bio (GRTS), ProPhase Labs (PRPH), Tonix Pharmaceuticals (TNXP), Atai Life Sciences (ATAI), Enanta Pharmaceuticals (ENTA), XBiotech (XBIT), Immutep (IMMP), and 23andMe (ME). These companies are all part of the "medical" sector.
Lantern Pharma (NASDAQ:LTRN) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership.
BioXcel Therapeutics has a consensus target price of $16.71, suggesting a potential upside of 798.62%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than Lantern Pharma.
BioXcel Therapeutics received 226 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 75.00% of users gave Lantern Pharma an outperform vote while only 67.23% of users gave BioXcel Therapeutics an outperform vote.
In the previous week, Lantern Pharma and Lantern Pharma both had 4 articles in the media. Lantern Pharma's average media sentiment score of 0.55 beat BioXcel Therapeutics' score of 0.55 indicating that Lantern Pharma is being referred to more favorably in the media.
Lantern Pharma has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.
Lantern Pharma has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -8,715.72%. Lantern Pharma's return on equity of -41.17% beat BioXcel Therapeutics' return on equity.
28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 6.9% of Lantern Pharma shares are held by insiders. Comparatively, 35.8% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Lantern Pharma has higher earnings, but lower revenue than BioXcel Therapeutics. Lantern Pharma is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Lantern Pharma and BioXcel Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Lantern Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lantern Pharma Competitors List
Related Companies and Tools
